Evaluation of Next Generation Receptor Technologies in OTFT Biosensors

OTFT 生物传感器中下一代受体技术的评估

• 批准号: 103312
• 金额: $ 8.96万
• 依托单位: NEUDRIVE LIMITED
• 依托单位国家: 英国
• 项目类别: Feasibility Studies
• 财政年份: 2017
• 资助国家: 英国
• 起止时间: 2017 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=103312
• 关键词: Evaluation; Next; Generation; Receptor; Technologies

The development of next generation point of care diagnostics is set to radically change the way in which health care is delivered. Portable, networked devices will deliver rapid test results from patient samples within a few minutes enabling accelerated medical decision making and patient stratification in primary care settings. These technologies will find application in diverse fields, for example cancer screening, acute and emergency care, management of chronic conditions, primary care and the tackling of antimicrobial resistance (AMR). Biosensors will be a central component of these next generation diagnostic products, however to maximise commercial potential there is an urgent need to provide specific and selective biosensors whilst reducing fabrication complexity and improving detector robustness. This must be achieved through a suitable mass production process and at a cost point that will enable adoption in the market. This project aims to demonstrate highly sensitive biomarker detection through the development of NeuDrive's organic thin film transistor (OTFT) biosensor platform. This will be achieved through its combination with novel platform technologies for biomolecular recognition, sourced from two innovative UK based SMEs.

下一代护理点诊断的发展将从根本上改变医疗保健的提供方式。便携式联网设备将在几分钟内提供患者样本的快速检测结果，从而加快医疗决策和初级保健环境中的患者分层。这些技术将在不同领域得到应用，例如癌症筛查、急性和紧急护理、慢性病管理、初级保健和应对抗菌素耐药性（AMR）。生物传感器将是这些下一代诊断产品的核心组成部分，然而，为了最大限度地发挥商业潜力，迫切需要提供特异性和选择性的生物传感器，同时降低制造复杂性并提高检测器的鲁棒性。这必须通过适当的大规模生产过程来实现，并且成本点将能够在市场上采用。该项目旨在通过开发NeuDrive的有机薄膜晶体管（OTFT）生物传感器平台来展示高灵敏度的生物标志物检测。这将通过与来自英国两家创新中小企业的生物分子识别新平台技术相结合来实现。